• Explore /
  • Poster
  • / Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).

Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).

Abstract Video & Slides Poster

Authors

null

J. Randolph Hecht

David Geffen School of Medicine, University of California, Los Angeles, CA

J. Randolph Hecht , Miklos Pless , Antonio Cubillo , Aitana Calvo , Hong Jae Chon , Chunxu Liu , Wendy Snyder , Emily Chan , Marya F. Chaney , Jason Alan Chesney , Aleix Prat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other IO-Related Topics

Clinical Trial Registration Number

NCT02509507

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3015)

DOI

10.1200/JCO.2020.38.15_suppl.3015

Abstract #

3015

Poster Bd #

79

Abstract Disclosures

Similar Posters

First Author: Siqing Fu

First Author: Lisa Zimmer

First Author: J. Randolph Hecht

First Author: Akihito Kawazoe